Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04493411 · ClinicalTrials.gov registry record · NA

Noninvasive Detection and Assessment of Therapy Response in Multiple Myeloma Using Whole-Body MRI

A NA study, sponsored by University of Texas Southwestern Medical Center.

Terminated
Registry status
NA
Development phase
21
Enrollment target

NCT04493411 is a NA study that was terminated before completion, run by University of Texas Southwestern Medical Center. The registered enrollment target is 21 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04493411, a NA study, was terminated before completion, sponsored by University of Texas Southwestern Medical Center.

TERMINATED
Registry status
NA
Development phase
21 participants
Enrollment target

Study Summary

This study is designed to prospectively determine the sensitivity, specificity, and diagnostic accuracy of whole-body MRI (WBMRI) with Dual-Echo T2-weighted acquisition for Enhanced Conspicuity of Tumors (DETECT) for the detection of multiple myeloma. Subjects will undergo WBMRI and fluorodeoxyglucose (FDG) positron emission tomography (PET) for research purposes either at one time point for cross-sectional study or at four time points for longitudinal study: baseline, prior to bone marrow transplant (BMT), prior to maintenance therapy, and post BMT. The results of these imaging procedures will be compared to standard of care whole body x-ray and bone marrow biopsy results.

Interventions

  • PROCEDURE WBMRI
  • PROCEDURE Positron Emission Tomography/Computed Tomography (PET/CT)

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2020-11-30
Est. Completion 2024-04-12
Phase NA

What the Registry Record Tells You About NCT04493411

The ClinicalTrials.gov registry entry for NCT04493411 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which WBMRI is the first listed.

NCT04493411 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04493411 about?

NCT04493411 is a clinical study titled "Noninvasive Detection and Assessment of Therapy Response in Multiple Myeloma Using Whole-Body MRI". This study is designed to prospectively determine the sensitivity, specificity, and diagnostic accuracy of whole-body MRI (WBMRI) with Dual-Echo T2-weighted acquisition for Enhanced Conspicuity of Tumors (DETECT) for the detection of multiple myeloma. Subjects will undergo WBMRI and fluorodeoxygluc...

What is the current status of trial NCT04493411?

This trial is currently terminated. It is a NA study. The enrollment target is 21 participants. The study started on 2020-11-30. Estimated completion is 2024-04-12.

What interventions are being tested in trial NCT04493411?

The interventions under investigation include: WBMRI (PROCEDURE), Positron Emission Tomography/Computed Tomography (PET/CT) (PROCEDURE).

Who is sponsoring clinical trial NCT04493411?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.